Author

Jes Dietrich

Senior Scientist, Statens Serum Institut, Denmark - Cited by 7,397 - Vaccines - Immunology - Chlamydia - Streptococcus - Adjuvants

Biography

Jes Dietrich is currently working as a Project Manager in Vaccine development and antigen discovery. He have so far been involved in leading two tuberculosis vaccine candidates into clinical trials and have recently received 250 million DKr from Gates foundation to take a new enhanced Polio vaccine into a phase 3 clinical trial in 2016/17 (I am Principle Investigator on that project).  Currently he working as a Project Manager in infection and Immunology.manage projects aimed at understanding the interaction between infectious agents, such as Chlamydia, M.tb, Streptococcus Pyogenes and Polio virus, and the immune system. 
Title
Cited by
Year
A multistage tuberculosis vaccine that confers efficient protection before and after exposure
C Aagaard, T Hoang, J Dietrich, PJ Cardona, A Izzo, G Dolganov, ...Nature medicine 17 (2), 189-194, 2011201
616
2011
The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection
PL Lin, J Dietrich, E Tan, RM Abalos, J Burgos, C Bigbee, M Bigbee, ...The Journal of clinical investigation 122 (1), 303-314, 2012201
252
2012
Vaccine-induced th17 cells are maintained long-term postvaccination as a distinct and phenotypically stable memory subset
T Lindenstrøm, J Woodworth, J Dietrich, C Aagaard, P Andersen, ...Infection and immunity 80 (10), 3533-3544, 2012201
136
2012
The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity
R Billeskov, TT Elvang, PL Andersen, J DietrichPloS one 7 (6), e39909, 2012201
118
2012
Quality and vaccine efficacy of CD4+ T cell responses directed to dominant and subdominant epitopes in ESAT-6 from Mycobacterium tuberculosis
CS Aagaard, TTKT Hoang, C Vingsbo-Lundberg, J Dietrich, P AndersenThe Journal of Immunology 183 (4), 2659-2668, 2009200
116
2009
Vaccine-induced Th17 cells are established as resident memory cells in the lung and promote local IgA responses
D Christensen, R Mortensen, I Rosenkrands, J Dietrich, P AndersenMucosal immunology 10 (1), 260-270, 2017201
116
2017
ESAT-6 (EsxA) and TB10. 4 (EsxH) based vaccines for pre-and post-exposure tuberculosis vaccination
T Hoang, C Aagaard, J Dietrich, JP Cassidy, G Dolganov, GK Schoolnik, ...PloS one 8 (12), e80579, 2013201
99
2013
Non-clinical efficacy and safety of HyVac4: IC31 vaccine administered in a BCG prime–boost regimen
YAW Skeiky, J Dietrich, TM Lasco, K Stagliano, V Dheenadhayalan, ...Vaccine 28 (4), 1084-1093, 2010201
88
2010
Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B–ESAT6 fusion protein
LJ Hall, S Clare, D Pickard, SO Clark, DLF Kelly, M Abd El Ghany, C Hale, ...Vaccine 27 (49), 6894-6904, 2009200
52
2009
Adaptive immunity against Streptococcus pyogenes in adults involves increased IFN-γ and IgG3 responses compared with children
R Mortensen, TN Nissen, T Blauenfeldt, JP Christensen, P Andersen, ...The Journal of Immunology 195 (4), 1657-1664, 2015201
52
2015
Combinatorial synthetic peptide vaccine strategy protects against hypervirulent CovR/S mutant streptococci
M Pandey, R Mortensen, A Calcutt, J Powell, MR Batzloff, J Dietrich, ...The Journal of Immunology 196 (8), 3364-3374, 2016201
43
2016
Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01
J Dietrich, LV Andreasen, P Andersen, EM AggerPLoS One 9 (6), e100879, 2014201
40
2014
Improved long-term protection against Mycobacterium tuberculosis Beijing/W in mice after intra-dermal inoculation of recombinant BCG expressing latency associated antigens
ST Reece, A Nasser-Eddine, J Dietrich, M Stein, U Zedler, ...Vaccine 29 (47), 8740-8744, 2011201
39
2011
Difference in TB10.4 T‐cell epitope recognition following immunization with recombinant TB10.4, BCG or infection with Mycobacterium tuberculosis
R Billeskov, MV Grandal, C Poulsen, JP Christensen, N Winter, ...European journal of immunology 40 (5), 1342-1354, 2010201
32
2010
Lactobacillus plantarum producing a Chlamydia trachomatis antigen induces a specific IgA response after mucosal booster immunization
K Kuczkowska, I Myrbråten, L Øverland, VGH Eijsink, F Follmann, ...PLoS One 12 (5), e0176401, 2017201
31
2017
Differential influence of nutrient-starved Mycobacterium tuberculosis on adaptive immunity results in progressive tuberculosis disease and pathology
J Dietrich, S Roy, I Rosenkrands, T Lindenstrøm, J Filskov, ...Infection and immunity 83 (12), 4731-4739, 2015201
28
2015
Comparing adjuvanted H28 and modified vaccinia virus ankara expressing H28 in a mouse and a non-human primate tuberculosis model
R Billeskov, JP Christensen, C Aagaard, P Andersen, J DietrichPloS one 8 (8), e72185, 2013201
27
2013
Parenteral vaccination protects against transcervical infection with Chlamydia trachomatis and generate tissue-resident T cells post-challenge
NDNT Nguyen, AW Olsen, E Lorenzen, P Andersen, M Hvid, F Follmann, ...npj Vaccines 5 (1), 7, 2020202
27
2020
Local Th17/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes
R Mortensen, D Christensen, LB Hansen, JP Christensen, P Andersen, ...PLoS One 12 (4), e0175707, 2017201
26
2017
A liposome-based adjuvant containing two delivery systems with the ability to induce mucosal immunoglobulin A following a parenteral immunization
D Christensen, L Bøllehuus Hansen, R Leboux, W Jiskoot, ...ACS nano 13 (2), 1116-1126, 2019201
24
2019

Referred From: https://scholar.google.com/citations?hl=en&user=z3NIfioAAAAJ

Cited by
Citations 7397
h-index 43
i10-index 66
Recommended Journals
Open Access Journals